Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHK4951 in Diabetic Macular Edema
NCT06116916Phase 2Active, not recruiting
- Sponsor
- Kyowa Kirin
- Start
- Jan 2024
- Primary completion
- Oct 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of KHK4951 in diabetic macular edema (DME) (3 arms), sponsored by Kyowa Kirin. Primary endpoint: Reduction of 15 or more letters in Best Corrected Visual Acuity at 36 weeks. Started Jan 2024; status: active, not recruiting.
02
Drugs
KHK4951
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06116916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116916.